使用安布罗克索尔作为治疗Gaucher病的疗法
Xia Zhan1, Huiwen Zhang1, Gustavo H B Maegawa2
1Department of Pediatric Endocrinology and Genetics, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
JAMA network open
|June 21, 2023
概括
对于缺乏酶替代疗法的高氏病 (GD) 患者,安布罗克索治疗是安全有效的. 治疗改善了血液学参数,减少了器官体积,并使生物标志物正常化,特别是在年轻患者中.
科学领域:
- 生物化学 生物化学
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 安布罗克索尔可以增强错误折叠的葡萄糖大脑蛋白酶变体的稳定性.
- 氏病 (Gaucher disease,GD) 是一种需要治疗的遗传性疾病.
研究的目的:
- 评估阿姆布罗克索尔治疗GD患者的血液和内脏结果.
- 评估安布洛克索在没有其他治疗的GD患者中的生物标志物变化和安全性.
主要方法:
- 口服安布罗克索尔给了28名无法负担酶替代疗法的GD患者.
- 随着时间的推移,测量了血液学参数,和肝体积以及生物标志物 (胆三酶,葡萄糖素).
主要成果:
- 长达2.6年的安布罗克索治疗改善了血红蛋白和血小板计数.
- 脏和肝脏的体积显著减少.
- 生物标志物显示显著降低:奇托酶活性43.1%和葡萄糖素34.1%.
- 年轻的患者表现出更快速和明显的改善.
结论:
- 长期的安布罗克索治疗对高氏病患者来说是安全和有益的.
- 在症状较轻的患者和在较年轻时接受治疗的患者中,改善更为显著.
相关概念视频
Parkinson's Disease: Treatment
303
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
303
Cholinergic Antagonists: Therapeutic Uses
784
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
784
Direct-Acting Cholinergic Agonists: Therapeutic Uses
797
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
797
Alzheimer's Disease: Treatment
223
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
223
Cystic Fibrosis: Management
199
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
199
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
161
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
161


